News
ABUS
--
0.00%
--
BRIEF-Arbutus Biopharma Increased Size Of Board By One Member And Appointed Tram Tran
reuters.com · 11/12 12:42
BRIEF-Arbutus Biopharma Appoints Tram Tran To Its Board Of Directors
reuters.com · 11/11 12:33
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28...
Globe Newswire · 11/10 21:30
Arbutus to Participate at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with diffe...
GlobeNewswire · 11/10 12:30
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Benzinga · 11/08 13:24
JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $9
JMP Securities analyst Jason Butler maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price target from $7 to $9.
Benzinga · 11/08 12:12
26 Stocks Moving in Monday's Pre-Market Session
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus.
Benzinga · 11/08 11:51
BRIEF-Arbutus Biopharma Corp Files For Mixed Shelf Of Up To $250 Million – SEC Filing
reuters.com · 11/04 21:53
Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 11/04 12:55
Arbutus Biopharma Q3 EPS $(0.24), Inline, Sales $3.34M Beat $2.38M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year.
Benzinga · 11/04 12:27
Arbutus Announces Late-Breaker Abstract Accepted For Presentation At AASLD - The Liver Meeting 2021
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms
Benzinga · 11/01 20:19
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily...
Globe Newswire · 11/01 20:05
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/28 19:05
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for peo...
GlobeNewswire · 10/21 11:30
21 Stocks Moving in Monday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine candidate VLA2001.
Benzinga · 10/18 11:02
Watching Arbutus Shares As Judge In Moderna v Arbutus Case Will Hear Appeals Thursday Morning
https://twitter.com/danravicher/status/1446109996152803333
Benzinga · 10/07 14:07
Thinking about buying stock in Tata Motors, New Fortress Energy, Arbutus Biopharma, US Well Services, or Progenity?
InvestorsObserver issues critical PriceWatch Alerts for TTM, NFE, ABUS, USWS, and PROG.
PR Newswire · 10/07 12:30
Arbutus to Participate in October Investor Conferences
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat corona...
GlobeNewswire · 09/28 11:30
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Zacks · 09/27 12:32
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat corona...
GlobeNewswire · 09/21 11:30
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.